ALMDP — Medesis Pharma SA Share News
0.000.00%
Last trade - 00:00Brief: Medesis Pharma Signs A Partnership With Partner International
Brief: Medesis Pharma Issues Bond Financing With Maximum Potential Nominal Amount Of EUR 2.5 Mln
Brief: Medesis Pharma Creates Council For Neurodegenerative Diseases
Brief: Medesis Pharma H1 Operating Loss Widens To 1.8 Million Euros
Brief: Medesis Pharma Announces First Inclusions Of Patients In Alzheimer's Disease Phase II Clinical Trial
French and Benelux stocks-Factors to watch
Brief: Medesis Pharma Says Positive Results In Development Programme Of NanoManganese
Brief: Medesis Pharma FY Turnover Amounts To EUR 73,050
Medesis leaps as much as 75% as it seeks funding for anti-nuclear drugs
Medesis shares leap 75% on funding request for drugs against nuclear threat (updated)
France's Medesis Pharma surges on funding request for nuclear contamination drugs
Medesis shoots up on push for antinuclear drugs development
Brief: Medesis Pharma Plans To Accelerate Development Of Three Anti-Nuclear Drugs
Brief: Medesis Pharma Wins Brazil Approval For Phase II Nanomanganese® Test
Brief: Medesis Pharma H1 Net Loss Widens To 1.1 Million Euros
Brief: Medesis Pharma And Transgene Announce Joint European Patent
Brief: Medesis Pharma: ANSM Refuses To Authorise Clinical Study Of NanoManganese In COVID-19
Brief: Medesis Pharma Says NanosiRNA HD Clinical Results Could Be Known Mid-2023
Brief: Medesis Pharma FY Operating Loss Widens To EUR 1.0 Mln